Ep 20 - A Conversation with Jeff Galvin of AGT

Jeff Galvin, CEO and founder of American Gene Technologies® (AGT™) and Addimmune™, is dedicated to curing humanity's most deadly diseases through gene and cell therapy. Addimmune, a spin-off company from AGT, is developing a potential cure for HIV. Building on the success of AGT’s HIV clinical trial, Addimmune is focused on developing and commercializing an effective and lasting cure for HIV using gene and cell therapy. Galvin has always been fascinated by the healing potential of biotechnology. He views the human cell as a biological computer, with DNA functioning as its software operating system. Similar to man-made computers, a cell's OS can sometimes have glitches or errors that cause it to function abnormally, leading to life-threatening diseases. He believes that the best way to cure these diseases is by fixing the underlying DNA, essentially tweaking the cell’s software code to eliminate the glitch. This vision and the techniques for repairing a cell’s DNA continually drive him, AGT, and Addimmune toward more innovation. Galvin earned his BA degree in Economics from Harvard in 1981 and has more than 30 years of business and entrepreneurial experience, including founding or holding executive positions at various Silicon Valley startups. Several of his companies have been taken public and/or sold to public companies.